Project Grant HT94252510039
Award Date
1/1/25
Completion Date
12/31/26
Dollars Obligated
$443K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
The U.S. Defense Health Agency awarded a $1,626,932.00 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on March 1, 2025, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. Specifically, the grant will fund the "Detection and Quantification of Early Motor...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $2,424,067 project grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the "DEVELOPMENT OF ANTI-DYT1 DYSTONIA GENE EDITING THERAPIES". The grant, with a performance period from Jul 1, 2024 to Jun 30, 2028, will support MGH's research to develop new gene editing therapies for treating DYT1 dystonia, a rare neurological disorder. As...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,234,505.00 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award supports research to cotarget the tumor microenvironment and revolutionize antibody-drug conjugate...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,644,309 project grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct advanced biomedical research focused on "FUNCTIONAL MOLECULAR NETWORKS MODIFYING HIF2A ACTIVITY IN VHL TUMORS". The grant, awarded on February 1, 2025, will support MGH's innovative research efforts to transform healthcare for military service members,...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), was awarded a $577,094 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research aimed at "Redirecting Viral Immunity to Eradicate Low Tumor Mutation Burden Lung Cancers." The award period runs from Aug 31, 2023 to Aug 29, 2025. As a leading academic medical center and research institution, MGH utilizes its...
The U.S. Department of Defense (DoD) awarded a $334,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), on September 15, 2023. The award supports a 2-year research project titled "TARGETING THE NF-KB PATHWAY TO TREAT NF1-DEFICIENT TUMORS." Through this funding, MGH will conduct biomedical research to investigate novel approaches for treating tumors caused...
The federal Project Grant award of $999,806.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to study innate lymphoid cells as new targets to reduce vascularized composite tissue transplant rejection. The award, which runs from September 30, 2024 to September 29, 2027, will enable MGH to conduct innovative biomedical research,...
The federal Project Grant award with ID HT94252410711, titled "TARGETING HETEROGENEITY IN NF2-MUTANT TUMORS," was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $1,568,220.00 grant, with a performance period from Sep 15, 2024 to Sep 14, 2027, was awarded to The General Hospital Corporation's Research Management Division, doing business as Massachusetts General Hospital (MGH). Through this funding, MGH will conduct...
The U.S. Defense Health Agency awarded The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a $1,140,766 Project Grant under the Military Medical Research and Development (CFDA 12.420) program. The award, effective September 1, 2024 through August 31, 2027, will fund a novel mHealth balance assessment and rehabilitation project using computer vision and AI for patients with neurofibromatosis type 2 (NF2). MGH, as the primary research institution, will...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program provides $320,000.00 in funding to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on "GAMMA DELTA T CELL LIGANDS IN MS". The award period runs from November 1, 2024 to October 31, 2026. As a major recipient of federal research funding, MGH will leverage its extensive...